United Therapeutics (NASDAQ:UTHR) COO Sells $9,616,725.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total value of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The shares were sold at an average price of $392.21, for a total value of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The shares were sold at an average price of $397.41, for a total value of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $426.21 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $459.48. The business has a 50 day simple moving average of $395.28 and a two-hundred day simple moving average of $331.38. The firm has a market capitalization of $19.23 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 4.60 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the firm earned $5.85 EPS. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Morgan Stanley upped their target price on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America upped their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $461.62.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock valued at $1,374,001,000 after acquiring an additional 15,312 shares during the last quarter. AQR Capital Management LLC lifted its position in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Invesco Ltd. lifted its position in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the last quarter. Assetmark Inc. raised its holdings in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after buying an additional 197,384 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 0.7% in the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after buying an additional 4,145 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.